Metformin in obesity, cancer and aging: addressing controversies
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Metformin, an oral anti-diabetic drug, is being considered increasingly for treatment and prevention of cancer, obesity as well as for the extension of healthy lifespan. Gradually accumulating discrepancies about its effect on cancer and obesity can be explained by the shortage of randomized clinical trials, differences between control groups (reference points), gender- and age-associated effects and pharmacogenetic factors. Studies of the potential antiaging effects of antidiabetic biguanides, such as metformin, are still experimental for obvious reasons and their results are currently ambiguous. Here we discuss whether the discrepancies in different studies are merely methodological or inherently related to individual differences in responsiveness to the drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms
Calle, E. E., & Kaaks, R. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1408 · Cited by 3,613 · cited 2×
“Obesity is associated with increased mortality and, hence, decreased lifespan [2, 4].”
BackgroundMetformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · cited 1×
“The wave of interest, with periodical decays and increasing surges, was associated with the attempts to use antidiabetic biguanides to control body weight and tumor growth [8-13].”
BackgroundGiovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124 · cited 1×
“Accordingly, some studies found no association between metformin therapy and breast cancer incidence in diabetic women [41, 42].”
BackgroundRisk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub4 · Cited by 893
Onken, B., & Driscoll, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008758 · Cited by 671 · cited 1×
“Metformin has been shown to slow-down lipofuscin accumulation, enhance locomotor activity and increase mean lifespan in Caenorhabditis elegans nematodes in a dose-dependent manner within concentration range of 1 to 50 mM in culture medium [78].”
BackgroundTzoulaki, I., Molokhia, M., Curcin, V., Little, M. P., Millett, C. J., Ng, A., Hughes, R. I., Khunti, K., Wilkins, M. R., Majeed, A., et al. (2009) · BMJ · doi:10.1136/bmj.b4731 · Cited by 444
Anisimov, V. N., Berstein, L. M., Egormin, P. A., Piskunova, T. S., Popovich, I. G., Zabezhinski, M. A., Kovalenko, I. G., Poroshina, T. E., Semenchenko, A. V., Provinciali, M., et al. (2005) · Experimental Gerontology · doi:10.1016/j.exger.2005.07.007 · Cited by 402
Self-citationMetformin slows down aging and extends life span of female SHR mice
Anisimov, V. N., Berstein, L. M., Egormin, P. A., Piskunova, T. S., Popovich, I. G., Zabezhinski, M. A., Tyndyk, M. L., Yurova, M. V., Kovalenko, I. G., Poroshina, T. E., et al. (2008) · Cell Cycle · doi:10.4161/cc.7.17.6625 · Cited by 348
Self-citationAnisimov, V. N., Berstein, L. M., Popovich, I. G., Zabezhinski, M. A., Egormin, P. A., Piskunova, T. S., Semenchenko, A. V., Tyndyk, M. L., Yurova, M. N., Kovalenko, I. G., et al. (2011) · Aging · doi:10.18632/aging.100273 · Cited by 285 · cited 5×
“Noteworthy is that metformin tends to be more efficient upon earlier onset of its application ([88] and Table 1).”
BackgroundSelf-citationMeta-analysis: metformin treatment in persons at risk for diabetes mellitus
Salpeter, S. R., Buckley, N. S., Kahn, J. A., & Salpeter, E. E. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.09.016 · Cited by 248
Metformin and Other Biguanides in Oncology: Advancing the Research Agenda
Pollak, M. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0175 · Cited by 240 · cited 3×
“Of special interest is the question of whether metformin is the most appropriate biguanide for oncology [36, 53, 95] and beyond.”
BackgroundEffects of Metformin on Body Weight and Body Composition in Obese Insulin-Resistant Children
Yanovski, J. A., Krakoff, J., Salaita, C. G., McDuffie, J. R., Kozlosky, M., Sebring, N. G., Reynolds, J. C., Brady, S. M., & Calis, K. A. (2011) · Diabetes · doi:10.2337/db10-1185 · Cited by 193 · cited 2×
“The main and uniform conclusion presented herein is that metformin acts ‘selectively’ and its effects on obesity, cancer, and lifespan experiments vary depending on gender [90], age [24, 25, 51, 88] and other factors, including tumor location (tissue specificity).”
BackgroundBayraktar, S., Hernadez‐Aya, L. F., Lei, X., Meric‐Bernstam, F., Litton, J. K., Hsu, L., Hortobagyi, G. N., & Gonzalez‐Angulo, A. M. (2012) · Cancer · doi:10.1002/cncr.26439 · Cited by 176 · cited 1×
“It should be noted that when cancer-related mortality, rather than cancer risk, is assessed in diabetics (once again, at ages mainly above 50), the belief that their survival is better in metformin-treated groups is not always confirmed for prostate and breast cancer [48, 49], although one study does suggest better su…”
BackgroundDelahanty, L. M., Pan, Q., Jablonski, K. A., Watson, K. E., McCaffery, J. M., Shuldiner, A., Kahn, S. E., Knowler, W. C., Florez, J. C., Franks, P. W., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1328 · Cited by 116
Nieuwenhuis-Ruifrok, A. E., Kuchenbecker, W. K. H., Hoek, A., Middleton, P., & Norman, R. J. (2008) · Human Reproduction Update · doi:10.1093/humupd/dmn043 · Cited by 110 · cited 1×
“It is not clear whether this can be explained by metformin underdosage [22], although a recent meta-analysis indicates that both drug dose and duration of treatment are highly relevant [23].”
BackgroundOCT1 expression in adipocytes could contribute to increased metformin action in obese subjects
Moreno-Navarrete, J. M., Ortega, F. J., Rodríguez-Hermosa, J.-I., Sabater, M., Pardo, G., Ricart, W., & Fernández-Real, J. M. (2011) · Diabetes · doi:10.2337/db10-0805 · Cited by 100 · cited 1×
“Therefore, OCT1 may be a potential marker of metformin accumulation in the tissue [26].”
BackgroundMetformin induces oxidative stress in white adipocytes and raises uncoupling protein 2 levels
Anedda, A., Rial, E., & González-Barroso, M. M. (2008) · Journal of Endocrinology · doi:10.1677/joe-08-0278 · Cited by 98 · cited 1×
“This process is clearly increased in the adipose tissue in obese patients [28], and although metformin is known to have an antioxidant activity, especially in diabetes [29], this drug can enhance free radical generation in differentiating adipocytes [30].”
BackgroundHalicka, H. D., Zhao, H., Li, J., Traganos, F., Zhang, S., Lee, M., & Darzynkiewicz, Z. (2011) · Aging · doi:10.18632/aging.100397 · Cited by 53 · cited 1×
“Among the most discussed targets of metformin are AMPK activity and AMPrelated signaling, glycation reactions and glycation endproducts, mitochondrial membranes, reactive oxygen species generation, epigenetic mechanisms, pluripotent stem cells, cell proliferative senescence and mTOR pathway [7, 71, 73-77].”
Background
Cited by
The Search for Antiaging Interventions: From Elixirs to Fasting Regimens
de Cabo, R., Carmona-Gutierrez, D., Bernier, M., Hall, M. N., & Madeo, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.031 · Cited by 345
Metformin: A Hopeful Promise in Aging Research
Novelle, M. G., Ali, A., Diéguez, C., Bernier, M., & de Cabo, R. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025932 · Cited by 178
Reprogramming aging and progeria
Freije, J. M., & López-Otín, C. (2012) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2012.08.009 · Cited by 46
Espinoza, S. E., Wang, C.-P., Tripathy, D., Clement, S. C., Schwenke, D. C., Banerji, M. A., Bray, G. A., Buchanan, T. A., Henry, R. R., Kitabchi, A. E., et al. (2016) · AGE · doi:10.1007/s11357-016-9946-6 · Cited by 14
Metadata
- Authors
- Berstein, L. M.
- Venue
- Aging
- Publisher
- Impact Journals, LLC
- Published
- 2012-04-30
- Volume
- 4
- Issue
- 5
- Pages
- 320-329
- ISSN
- 1945-4589 (ISSN-L)
- OpenAlex
- W2169344707
- Cited by
- 85
- References
- 19
- FWCI
- 5.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.